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CD30 antigen, originally identified as a cell surfacemarker of the malignant Hodgkin and Reed-Sternberg (HRS) cells in Hodgkin’s lymphoma by
the use of the Ki-1 monoclonal antibody, is a transmem-
brane glycoprotein member of the tumor necrosis factor
(TNF) receptor superfamily.1 In lymphoid cells, CD30 is an
activation marker inducible in vitro by mitogenic signals
and viral stimulation, and its expression is detected in a
small number of immunoblasts in benign lymphatic tis-
sues.2 In pathological conditions, CD30 is found at vari-
able levels in different lymphomas of B-cell or T-cell deri-
vation, and in several reactive conditions (Table 1).
However, strong and homogeneous CD30 expression in
most neoplastic cells is restricted to fewer entities, mainly
three groups of lymphoid neoplasms: (i) classical
Hodgkin’s lymphoma, (ii) anaplastic large cell lymphomas
(ALCL), and (iii) primary cutaneous CD30+ T-cell lympho-
proliferative disorders.3 For diagnostic purposes, the detec-
tion of CD30 is of particular value as a hallmark feature,
albeit not specific, for the identification of these entities.
The disorders most characteristically associated with
CD30 are distinct clinico-pathological entities - interest-
ingly with some morphological similarity, as
‘Hodgkin’s-like’ features may be encountered in both
ALCL and primary cutaneous CD30+ lymphoprolifera-
tive disorders. Although there has been a lot of specula-
tion in the past about the relationship and possible over-
lap between classical Hodgkin’s lymphoma and ALCL,
it is now clear that these are biologically distinct entities
of different cellular derivation (B-cell versus T-cell,
respectively). Historically, CD30 was instrumental in
identifying ALCL as lymphomas composed of large
cells showing homogeneous expression of CD30 at high
levels, and characterized by cohesive growth and pecu-
liar ‘anaplastic’ cytomorphological features.4 Among
these, a small subset of cases of B-cell derivation repre-
sent variants of diffuse large B-cell lymphoma.
Nowadays, the designation ALCL is restricted to cases
of T-cell derivation. These overall infrequent neoplasms
involving lymph nodes and/or extranodal sites comprise
so-called typical ‘hallmark cells’ - characterized by an
eccentric horseshoe-shaped nucleus and a prominent
eosinophilic Golgi region. Anaplastic lymphoma kinase
(ALK) gene status was found to be another critical
parameter to characterize two subsets of ALCL.5
Molecularly defined ALK-positive ALCL is mostly a dis-
ease of children and young adults, carries a relatively
good prognosis and comprises a morphological spec-
trum including variants deviating from the common
type by the presence of only occasional ‘hallmark’
tumor cells and/or an associated reactive background.
Conversely, ALK-negative ALCL affects older individu-
als and is associated with a worse prognosis, closer to
that of peripheral T-cell lymphoma, not otherwise spec-
ified (PTCL, NOS).6 The view of ALK-positive and ALK-
negative ALCL as two variants of the same entity
evolved towards the concept of two separate disease
entities in the current WHO classification of hematolog-
ic malignancies.3 Although the majority of ALCL occur
as primary systemic disorders, a subset of ALK-negative
ALCL – referred to as primary cutaneous ALCL - occurs
primarily as single or multifocal tumor lesions in the
skin, usually remains localized to the skin, may undergo
spontaneous regression and generally has a favorable
prognosis. Because of overlapping clinical and patholog-
ical features with lymphomatoid papulosis, a clinically
benign recurring skin lymphoproliferative disease com-
posed of large atypical ‘anaplastic’ CD30+ cells admixed
with an inflammatory background, both primary cuta-
neous ALCL and lymphomatoid papulosis are consid-
ered within the spectrum of primary cutaneous CD30+
T-cell lymphoproliferative disorders. Figure 1 provides a
synoptic view of CD30+ lymphoproliferations of T-cell
derivation.
A peculiar feature of ALCL is that, despite the pres-
ence of monoclonal T-cell receptor (TCR) gene
rearrangement indicative of T-cell lineage derivation, its
manifestations of a T-cell immunophenotype are usually
limited. Indeed, ALCL tumor cells usually show reduced










may even have an apparent ‘null cell’ phenotype, with the
most commonly preserved antigens being CD2, CD4 and
CD45.6,7 The usual negativity for CD3 has been a focus of
interest given its potential functional consequences, since
CD3 molecules are associated with the TCR and trans-
duce the signal of TCR engagement to ZAP-70 tyrosine
kinase. In 2004, Bonzheim et al. from Würzburg showed
that ALCL lack expression of TCR molecules and have
markedly reduced or absent expression of ZAP-70.8
In this issue of the journal, Geissinger et al. expand their
previous work and report on the disturbed expression of
the TCR/CD3 complex and associated signaling molecules
in CD30+ T-cell lymphoproliferations.9 The analysis was
conducted by immunohistochemistry on a large series of
tissues comprising 71 cases of systemic ALCL (33 ALK-
positive and 38 ALK-negative) and 19 primary cutaneous
CD30+ lymphoproliferative disorders  (10 cases of primary
cutaneous ALCL and 9 of lymphomatoid papulosis) in
comparison to 20 cases of PTCL, NOS. They found ran-
dom losses in various combinations of the TCRa/β and
the four CD3 subunits (γ, δ, ε and ζ chains) in most cases
of systemic and cutaneous CD30+ lymphoproliferative dis-
orders, contrasting with the homogeneous expression in
most cases of PTCL, NOS. Regarding the TCR signaling
pathway, in addition to ZAP-70, several other down-
stream mediators of the pathway (Lck, LAT and NFATc1)
were down-regulated in CD30+ T-cell lymphoprolifera-
tions. Within the whole group of CD30+ T-cell lympho-
proliferations, there was a tendency for a continuum of
abnormalities which were, overall, maximal in ALK-posi-
tive ALCL, intermediate in ALK-negative ALCL and partial
in primary cutaneous CD30+ lymphoproliferative disor-
ders. The applicability of these markers in hematopathol-
ogy practice may be hampered by the complexity of the
antibody panel and variability of the expression patterns.
Although the data presented suggest that loss of the T-cell
phenotype is specific to ALCL rather than PTCL, NOS, the
diagnostic value of this feature remains to be defined by
focusing the analysis on cases with diagnostically chal-
lenging borderline features.
The characterization of T-cell identity loss as a feature
shared by CD30+ lymphoproliferations expands the recent
documentation, by Ambrogio et al., of an extensive loss of
T-cell-specific molecules, including CD3ε, ZAP-70, LAT
and SLP76, related to TCR signaling in systemic ALCL.10
Interestingly, this is also in line with genome-wide expres-
sion profiling studies in which fairly similar molecular sig-
natures and pathways have been found for systemic ALCL
irrespective of ALK gene rearrangements,11-13 while few
differences have been found between cutaneous and sys-
temic cases  of ALCL.14 In particular, the level of similarity
observed between the neoplastic cells in systemic ALK-
negative ALCL and primary cutaneous CD30+ lymphopro-
liferations is noteworthy as these conditions usually have
clearly different clinical presenting features and evolution.
A possibility is that, despite similar molecular profiles, dis-
tinct signaling pathways are activated in the different enti-
ties, and/or triggering of similar pathways may induce dis-
tinct effects. For example the effects of CD30 stimulation
by agonistic antibodies or its engagement with CD30-lig-
and have been shown to vary according to the cell type, as
they are basically absent in Hodgkin’s-like cells while
inducing decreased proliferation in ALCL cells.15,16 The
specificity of the microenvironment linked to the anatom-
ic site and/or that of the tumor-associated reactive cellular
infiltrate may also be determinant in modulating the prop-
erties and growth of the neoplastic cells. 
The association between strong CD30 expression and
altered expression of T-cell-specific molecules in CD30+ T-
cell lymphoproliferations calls into question the possibility
of a causal and/or functional relationship. Deregulated
CD30 expression in ALCL has been linked to activation of
transcription factors of the AP-1 family, including c-Jun
and JunB.17,18 Regarding the expression of transcription fac-
tors involved in the regulation of the TCR/CD3 complex
in CD30+ lymphoproliferations, Geissinger et al. identified
some defects (involving especially TCF-1 and TCF-
1a/LEF-1) in the whole group of CD30+ cases; however, in
the absence of clear-cut correlations at the level of single
cases they concluded that transcriptional dysfunction is
probably not the primary cause of TCR/CD3 loss. 
In ALK-positive ALCL, experimental data provide evi-
dence that both CD30 expression and down-regulation of
T-cell molecules are regulated by NPM-ALK tyrosine
kinase activity. The activation of CD30 transcription has
been shown to be mediated by JunB, while TCR/CD3
silencing has been linked to NPM-ALK-mediated STAT3
activation and involves epigenetic silencing by hyperme-
thylation.10,19 For other CD30+ T-cell lymphoproliferations
the primary oncogenic alterations are unknown, and it is
unclear whether deregulation of CD30 and TCR/CD3 are
linked to a common aberration or occur independently.  
The characteristic loss of T-cell-specific molecules in a
subset of peripheral T-cell neoplasms provides a new
direction for further investigations. It will be of interest to
examine the biological and functional consequences of
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Table 1. Lymphoproliferations with CD30 expression.
Primary systemic
Classical Hodgkin’s lymphoma*
Anaplastic large cell lymphoma, ALK-positive*
Anaplastic large cell lymphoma, ALK-negative*
Subsets of diffuse large B-cell lymphoma
Anaplastic variant
Primary mediastinal large B-cell lymphoma
Primary effusion lymphoma
Subsets of peripheral T-cell lymphoma entities
EBV-positive B-cell lymphoproliferative disorders
Reactive lymphoid hyperplasias
Primary cutaneous
Primary cutaneous CD30-positive T-cell lymphoproliferative disorders*
- Primary cutaneous anaplastic large cell lymphoma*
- Lymphomatoid papulosis*
Mycosis fungoides, large cell variant
Subsets of non-epidermotropic cutaneous lymphomas
Reactive cutaneous lymphoproliferations
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Figure 1. CD30+ T-cell lymphopro-
liferations.
ALCL comprises sheets of large cells,
including hallmark cells with horseshoe-
shaped nuclei and a paranuclear Golgi
region. LyP comprises scattered large
anaplastic cells in an inflammatory back-
ground. The overlaps between the entities
featured on the right are: the interface
between PTCL, NOS, and ALK-negative
ALCL (primary systemic or cutaneous); the
interface between sALCL and cALCL as
sALCL may present in the skin and con-
versely primary cutaneous ALCL may dis-
seminate systemically; the interface
between cALCL and LyP as these represent
a continuum.
ALCL: anaplastic large cell lymphoma;
ALK: anaplastic lymphoma kinase; c: cuta-
neous; LyP: lymphomatoid papulosis;
PTCL, NOS: peripheral T-cell lymphoma, not
otherwise specified; s: systemic.
TCR/CD3 silencing. Since TCR silencing occurs as a
downstream effect of the oncogenic tyrosine kinase activ-
ity in ALK-positive ALCL, it is tempting to speculate that
it may be involved in the development of the malignant
phenotype. Indeed, TCR silencing appears to be an early
event in CD30+ T-cell lymphoproliferative disorders, as
exemplified in lymphomatoid papulosis. Moreover,
defects in CD3/TCR expression have been reported in
other forms of T-cell malignancies, including angioim-
munoblastic T-cell lymphoma and human T-cell lym-
photropic virus-associated T-cell proliferations, as well as
an early aberration in the clonal T-cell populations
encountered in the lymphocytic variant of the hypere-
osinophilic syndrome.20,21 Advances in the understanding
of the cell functions deregulated by TCR silencing in these
neoplasms are essential for assessing the potential thera-
peutic importance of restoring T-cell identity. Indeed, from
a therapeutic standpoint, alternative treatments are need-
ed for patients with relapsing or refractory forms of sys-
temic ALCL, and a small subset of poorly controlled cuta-
neous CD30+ lymphoproliferations. The development of
monoclonal antibodies targeting the CD30 molecule con-
stitutes a promising approach in such patients and could
be combined with other innovative treatment modalities
such as inhibitors of ALK activity for ALK-positive
tumors.22,23
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Invasive fungal diseases are associated with significantmorbidity and mortality among neutropenic patientsafter chemotherapy and in allogeneic hematopoietic
stem cell transplant (HSCT) recipients. Considering that it
is difficult to make an early diagnosis, the prophylaxis of
these complications is appealing. Prevention strategies are
based on environmental precautions and antimicrobial
agents. While there is a general agreement on the role of
air filtration in the control of airborne filamentous fungal
infections, the indication for pharmacological prophylaxis
is still debated.1
Until a few years ago, only fluconazole and itraconazole
had been evaluated in randomized, controlled trials for
primary antifungal prophylaxis in patients with hemato-
logic disorders.2-4 In view of the results of these studies,
international guidelines did not recommend primary anti-
fungal prophylaxis for all neutropenic patients, including
those who had undergone autologous HSCT or had acute
leukemia, and only recommended prophylaxis of Candida
infections with oral or intravenous fluconazole for allo-
geneic HSCT recipients during the period of neutropenia
until engraftment.5-7
In recent years, awareness of the epidemiological impact
of invasive aspergillosis and less common molds, including
zygomycetes, Fusarium species and Scedosporium species,
has increased worldwide. At the same time, new broad
spectrum and well tolerated antifungal drugs, in particular
second generation triazoles (posaconazole and voricona-
zole) and echinocandins, became available, and prospec-
tive, controlled trials have been conducted to investigate
their ability to prevent invasive fungal infections in high-
risk hematologic patients.8-10 Based on the above studies,
current international guidelines continue to recommend
the use of fluconazole until engraftment in patients who
have undergone allogeneic HSCT, and, for the first time,
recommend the use of a broad spectrum drug, oral
posaconazole, during intensive immunosuppressive thera-
py for graft-versus-host disease, and in patients with acute
myeloid leukemia or myelodysplastic syndromes during
remission induction chemotherapy.11-13 These recommen-
dations reflect important progresses obtained in the pre-
vention of invasive fungal infections, including those
caused by filamentous fungi, but they have been unable to
generate a consensus on the optimal prophylaxis of inva-
sive fungal infections in the complex scenario of hemato-
logic disorders, particularly in the transplant setting. This
problem has been underlined in a recent consensus
process by the Gruppo Italiano Trapianto di Midollo Osseo
(GITMO) which observed that key recommendations by
international guidelines imply various problems such as
the lack of any approved mold-active prophylaxis during
the engraftment phase in allogeneic HSCT, and the lack of
an intravenous formulation of posaconazole, which could
limit the use of this drug in patients unable to tolerate oral
medications or with altered intestinal absorption.14 Based
on the preliminary results of two controlled studies of pri-
mary prophylaxis with voriconazole in allogeneic HSCT
recipients during engraftment and graft-versus-host disease
phases, and pending publication as full papers, the 2009
updated European guidelines (ECIL 3) provisionally rec-
ommended the use of voriconazole in both phases of
HSCT.13
An evidence-based approach to secondary antifungal
prophylaxis in patients with a previous invasive fungal
infection who require further antileukemic treatment
remains even more challenging. An anti-infection strategy
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